Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) EPS (Weighted Average and Diluted) (2018 - 2025)

Voyager Therapeutics' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$0.47 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 21.67% year-over-year to -$0.47; the TTM value through Dec 2025 reached -$2.04, down 78.95%, while the annual FY2025 figure was -$2.04, 80.53% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.47 at Voyager Therapeutics, roughly flat from -$0.47 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $2.94 in Q1 2023 and bottomed at -$0.8 in Q2 2021.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.5 (2022), against an average of -$0.16.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 513.33% in 2022 before it skyrocketed 625.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.15 in 2021, then tumbled by 513.33% to -$0.62 in 2022, then skyrocketed by 291.94% to $1.19 in 2023, then crashed by 150.42% to -$0.6 in 2024, then grew by 21.67% to -$0.47 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's EPS (Weighted Average and Diluted) are -$0.47 (Q4 2025), -$0.47 (Q3 2025), and -$0.57 (Q2 2025).